Related Experiment Video
Updated: Jun 17, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Naptumomab estafenatox: a new immunoconjugate.
Matthew K Robinson1, R Katherine Alpaugh, Hossein Borghaei
1Fox Chase Cancer Center, Department of Medical Oncology, 333 Cottman Ave, Philadelphia, PA 19111, USA.
Naptumomab, an immunotoxin, shows promise in treating refractory solid tumors. Early trials indicate encouraging clinical activity and a unique mechanism of action for this novel cancer immunotherapy agent.
Area of Science:
- Immunotherapy
- Oncology
- Pharmacology
Background:
- Novel immunotherapies targeting malignancies are under investigation.
- Naptumomab is an immunotoxin demonstrating promising clinical activity in early-phase trials.
Purpose of the Study:
- To provide a comprehensive overview of naptumomab.
- To review preclinical and clinical data for naptumomab.
Main Methods:
- Review of preclinical studies.
- Analysis of published clinical trial data.
Main Results:
- Understanding of naptumomab's mechanism of action.
- Insights into its immunology and pharmacokinetics.
- Evaluation of its clinical activity in cancer treatment.
Conclusions:
- Naptumomab exhibits a distinct mechanism of action.
- It shows potential as an active agent for refractory solid tumors, including renal cell carcinoma.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...